All News

Non-pharm tx in TAK - not something we always think about but… Impressive effect of resistance exercise!! Not just in symptoms but also inflammatory markers Per Dr. Springer - even a stress ball could be enough for UE vascular health in these pt @RheumNow #ACR24 https://t.co/3O46gobbMX

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
The overview for #lupus nephritis tx. Triple therapy is preferred as first line due to: 1. RCTs (BLISS-LN & AURORA 1) showing improved outcomes w/ triple txs 2. Nephron loss happens with ongoing LN - time is kidney! @RheumNow #ACR24 https://t.co/IQo3q3O1pt

Links:

sheila RHEUMarampa ( View Tweet)
Abstract 1876: Developed a machine learning model w/ #SDoH covariates to accurately identify patients with SLE and ESRD in NIH All of US dataset @RheumNow #ACR24 https://t.co/TLDSiBZZPs

Links:

Akhil Sood MD AkhilSoodMD ( View Tweet)
Older adults with late-onset RA (LORA) with more erosive changes, even with DMARD use But is T2T met? LORA with higher DAS on diagnosis and yet 10% on bDMARD vs 26% of young-onset RA #ACR24 @RheumNow ABST#2224 https://t.co/dYs1JwcJeq

Links:

Jiha Lee JihaRheum ( View Tweet)
RA patients affected by frailty at a younger age in @VARA frailty associated with lower BMD But frailty is modifiable! #GeriRheum #ACR24 @RheumNow ABST#2140 https://t.co/BoTGoESB43

Links:

Jiha Lee JihaRheum ( View Tweet)
The 🫀is muscle‼️ 💥From the maestro herself @JuliePaikMD underscores why cardiac involvement in myositis can't be overlooked. 🔥Crucial insights with major implications for patient care and outcomes #acr24 @RheumNow @HopkinsMedicine @jhrheumatology https://t.co/mw6BvkdF2w

Links:

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)

A#2529 Disparities in JIA Outcome documentation, best practices, access to at-risk pts, agency and access - outcomes initially appeared to worsen - reflection of better documentation Improvement driven by pt global scores Disparity gap closed by 17% #ACR24 @RheumNow https://t.co/oOxs0jIvBK

Links:

Eric Dein ericdeinmd ( View Tweet)

#2259 💊 Anti-Obesity Meds in RA 📊 152 RA patients on semaglutide/tirzepatide 🔑 Findings 💥Significant ⬇️weight, BMI, ESR, CRP, lipids, pain VAS 💥Improved CVD risk ⛔ 15% GI side effects, 27% discontinued 🔎Study of impact on RA outcomes needed #ACR24 @RheumNow #ACRBest https://t.co/6LCTZl5173

Links:

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Dr. @karen_kc123 discusses the results of the VITAL study. - Long term use of Vit D3 2000IU was safe and decreased the incidence of all autoimmune dses by 22%. - It took a while to work but the effect dissipates once discontinued. @RheumNow #ACR24 @rheumarhyme https://t.co/mnwRsdZ06N

Links:

sheila RHEUMarampa ( View Tweet)
A#2532 Pre-existing AID for immunoRx? Excluded from trials 4 prior studies showed no diff in mortality w AID Propensity-matched cohort study Followed median 250 days Hazard ratio: 1.07 (unmatched), 0.97 (matched) - no diff. Mortality about 40% in grps @RheumNow #ACR24 https://t.co/zyVCPts6s6

Links:

Eric Dein ericdeinmd ( View Tweet)
Mental health, sex, and comorbidities are key factors in determining recalcitrant psoriatic arthritis (PsA). Key findings: - 21.7% of patients required ≥4 biologic/targeted synthetic DMARDs. - Female patients and those with depression were more likely to be recalcitrant. - No… https://t.co/I9YYoRnLwh https://t.co/VtnPceVLOZ

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
In earlier studies of Vit D, there were conflicting evidence as to whether it reduced or increased the risk of RA and #SLE @RheumNow #ACR24 @rheumarhyme https://t.co/PvjjmhHaOd

Links:

sheila RHEUMarampa ( View Tweet)

Phase 2 DAHLIA study in Sjogrens Anti-neonatal Fc receptor an “nipocalimab” w/remarkably encouraging results clinESSDAI significantly better at wk24, notably met QOL domains as well Finally getting good news in SjS! #ACR24 @RheumNow #ACRbest Abst#2527 https://t.co/e3uQmqJZ1o

Links:

Mike Putman EBRheum ( View Tweet)
📢 Late breaking #2002 ➡️In ICI-induced arthritis, patients (n=100) report worsened pain, fatigue, & physical function vs population norms. ➡️High disease activity worsens symptoms #acr24 @RheumNow @jhrheumatology

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)

📢Late-breaking #2003 🔑 Cappelli et al @jhrheumatology finds hip OA is NOT a significant risk factor for #ICI-IA 🔴#ICI-IA linked to lower mortality #ACR24 #ACRBest @RheumNow

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)

Fertility in RA. Improved outcomes in the T2T group. Abstr#1647 @RheumNow #ACR24 https://t.co/gLpY8enaEb

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Shifting Trends in Initial RA Treatment Approaches A recent study by Sparks et al (Abstract #0509) reveals evolving trends in disease-modifying antirheumatic drug (DMARD) usage for rheumatoid arthritis (RA) over two decades in the U.S. https://t.co/6FN0WayZZR #ACR24 https://t.co/dc3CiNpKmx

Links:

Dr. John Cush RheumNow ( View Tweet)
Abst#2413 SLE Cohort of > 2900 pts over 50 yrs - Prevalence of proteinuria at the time of SLE dx has not changed over the decades. Prevalence of proteinuria also did not change at 5 and 10 yrs after dx. Earlier use of HCQ has not led to a ⬇️in lupus nephritis. @RheumNow #ACRbest

TheDaoIndex KDAO2011 ( View Tweet)

A study exploring the benefits of treating RA patients to remission after achieving low disease activity (LDA). Key findings: - Among patients initially at LDA, achieving remission (CDAI ≤2.8) led to significantly better functional outcomes and reduced durable medical equipment… https://t.co/SNPKlRieur https://t.co/YIQNMf3Oap

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

Abst#1493 complete renal response (< 0.5 g/g w/< 10 mg/day pred); renal remission (UPCR < 0.3 g/g w/< 5 mg/day pred). 60 LN pts followed 3 yrs: 40% CRR & 19% RR. Pts not in CRR/RR had⬇️eGFR w/more decline in eGFR over time. No difference b/t CRR/ RR @rheumnow #ACRbest #ACR24

TheDaoIndex KDAO2011 ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×